Rosuvastatin in severe CKD — GPhC CRA MCQ

Correct answer: E — The rosuvastatin dose in severe renal impairment

This scenario assesses Rosuvastatin in severe CKD in a UK pharmacy practice context. Rosuvastatin exposure increases in renal impairment and high doses may be unsuitable in severe CKD. The best answer is Query the dose because severe renal impairment increases toxicity risk because it addresses the principal clinical, legal or safety issue before routine supply. The other options are less appropriate because they either miss the key risk, delay necessary review, or would not meet expected BNF, NICE, MEP, MHRA or GPhC practice standards.

Reference: https://www.pharmacyregulation.org/students-and-trainees/pharmacist-education-and-training/registration-assessment